However, in breast cancer patients, these regulatory switches are dysregulated, leading to the activation of numerous oncoproteins and the suppression of tumor suppressor proteins, ultimately contributing to the initiation and progression of breast cancer. Here, TCHP is linked to breast carcinoma.